0000000000066517

AUTHOR

Uwe Hillen

showing 9 related works from this author

The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma.

2013

Abstract Most patients with BRAFV600-mutant metastatic melanoma develop resistance to selective RAF kinase inhibitors. The spectrum of clinical genetic resistance mechanisms to RAF inhibitors and options for salvage therapy are incompletely understood. We performed whole-exome sequencing on formalin-fixed, paraffin-embedded tumors from 45 patients with BRAFV600-mutant metastatic melanoma who received vemurafenib or dabrafenib monotherapy. Genetic alterations in known or putative RAF inhibitor resistance genes were observed in 23 of 45 patients (51%). Besides previously characterized alterations, we discovered a “long tail” of new mitogen-activated protein kinase (MAPK) pathway alterations (…

MAPK/ERK pathwayMelanomaMedizin10177 Dermatology ClinicSalvage therapy610 Medicine & healthDabrafenibDrug resistanceBiologymedicine.diseaseBioinformaticsMicrophthalmia-associated transcription factorArticleProto-Oncogene Proteins B-rafOncologyCancer researchmedicine2730 OncologyVemurafenibmedicine.drug
researchProduct

Differential influence of vemurafenib and dabrafenib on patient lymphocytes despite similar clinical efficacy in melanoma

2014

Background: Since the majority of melanomas eventually become resistant and progress, combining selective BRAF inhibitors (BRAFi) with immunotherapies has been proposed to achieve more durable treatment responses. Here, we explored the impact of selective BRAFi on the hosts’ immune system. Patients and methods: Clinical data, whole blood counts (WBC) and serum lactate dehydrogenase (LDH) of 277 vemurafenib- and 65 dabrafenib-treated melanoma patients were evaluated. The frequency and phenotype of lymphocyte subpopulations were determined by flow cytometry while T cell cytokine secretion was measured by multiplex assays. Results: Progression-free survival (PFS) as well as overall survival (O…

lymphocytesmedicine.medical_treatmentT cellLymphocyte2720 HematologyMedizinT cells610 Medicine & healthPharmacology142-005 142-005melanomamedicineInterleukin 9dabrafenibVemurafenibtreatmentbusiness.industryMelanomaDabrafenibOriginal ArticlesHematologyImmunotherapymedicine.diseasemedicine.anatomical_structureOncology2730 OncologyvemurafenibCytokine secretionbusinessmedicine.drug
researchProduct

The concentration of para-phenylenediamine (PPD) for routine patch testing in a standard series needs to be redefined

2005

medicine.medical_specialtyPediatricsDose-Response Relationship Drugbusiness.industryDermatologyPatch TestsPhenylenediaminesPara phenylenediamineDermatologyPatch testing030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineGermany030220 oncology & carcinogenesisDermatitis Allergic ContactmedicineHumansImmunology and AllergyColoring AgentsbusinessContact Dermatitis
researchProduct

Patch testing in children--recommendations of the German Contact Dermatitis Research Group (DKG).

2007

Summary Allergic contact dermatitis occurs frequently in children. Patch testing is needed to identify the responsible allergens and should be performed in children. We recommend a panel of 12 contact allergens as a standard series in children from 6–12 years. Four additional contact allergens should be tested in case of a positive history or suggestive clinical picture. For patch testing in children, the allergens should be applied for 24 hours and the readings should be performed at 48 and 72 hours. Standardized patch testing makes it possible to systematically investigate allergic contact dermatitis and identify relevant allergens in children.

medicine.medical_specialtyDermatitisDermatologyPediatricsPatch testing030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineimmune system diseases030225 pediatricsGermanyotorhinolaryngologic diseasesmedicineHumansContact allergensPractice Patterns Physicians'Allergic contact dermatitisbusiness.industryrespiratory systemPatch Testsmedicine.diseaseDermatologyrespiratory tract diseases3. Good healthDermatitis Allergic ContactPractice Guidelines as TopicbusinessContact dermatitisJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
researchProduct

CXCR3-ligand-mediated skin inflammation in cutaneous lichenoid graft-versus-host disease.

2007

Background Lichenoid graft-versus-host disease (liGVHD) histologically shares several common features with other lichenoid dermatoses, such as cutaneous lupus erythematosus and lichen planus (LP), which collectively show a junctional infiltrate of cytotoxic lymphocytes with liquefaction of the basal layer ("interface dermatitis"). Because recent studies have shown a role for type I interferon (IFN)–associated inflammation, including lymphocyte recruitment via CXCR3 ligand interaction in cutaneous lupus erythematosus and LP, we hypothesized that similar mechanisms might also be involved in liGVHD. Methods Ten representative lesional skin biopsies taken from patients with different subsets of…

Myxovirus Resistance ProteinsChemokinePathologymedicine.medical_specialtyLichenoid EruptionsReceptors CXCR3CD3T-LymphocytesGraft vs Host DiseaseInflammationDermatitisDermatologyIn situ hybridizationCXCR3LigandsChemokine CXCL9Skin DiseasesGTP-Binding ProteinsMedicineCXCL10HumansLymphocytesRNA MessengerIn Situ Hybridizationbiologybusiness.industryLichen PlanusInterferon-alphaChemokine CXCL10stomatognathic diseasesImmunologyChronic DiseaseInterferon Type Ibiology.proteinCXCL9Immunohistochemistrymedicine.symptomEpidermisbusinessJournal of the American Academy of Dermatology
researchProduct

Consensus on performing skin biopsies, laboratory workup, evaluation of tissue samples and reporting of the results in patients with suspected cutane…

2014

Background Histopathological diagnosis including selection of lesions, the determination of the best point of time for biopsy and workup is not trivial in cutaneous graft-versus-host disease (GvHD). Objectives To develop interdisciplinary recommendations on performing, the laboratory work up and reporting of the results of skin biopsies in patients with suspected cutaneous GvHD. Methods A working group consisting of dermatopathologists, dermatologists, transplant-physicians and transplant-pathologists prepared recommendations for performing skin biopsies, laboratory workup and evaluation of tissue samples, and reporting of the results in patients with cutaneous GvHD. After achieving a conse…

medicine.medical_specialtyConsensusBiopsymedicine.medical_treatmentMedizinGraft vs Host DiseaseDermatologyDiseaseSkin Diseasesimmune system diseasesSurveys and QuestionnairesBiopsyHumansTransplantation HomologousMedicineIn patientSkinintegumentary systemmedicine.diagnostic_testbusiness.industryHistological TechniquesHematopoietic Stem Cell TransplantationImmunosuppressionCutaneous graft-versus-host diseaseDermatologyWork-upSurgeryTransplantationsurgical procedures operativeInfectious DiseasesAcute DiseaseChronic DiseaseSkin biopsybusiness
researchProduct

Late reactions to patch test preparations with reduced concentrations of p-phenylenediamine : a multicentre investigation of the German Contact Derma…

2011

Background. p-Phenylenediamine (PPD) 1% in petrolatum has been shown in a prospective study to elicit late reactions in 1.5% of routine patch tests, which may be indicative of patch test sensitization. Objectives. To assess the frequency of late reactions to reduced PPD patch test concentrations. Methods. In 1838 patients, PPD was tested at three concentrations (0.5% pet., group I; 0.4% pet., group II; and 0.35% pet., group III). Patch tests were read on D1 (D2) to D3 (D4); additional late readings were performed on D7, D14, and D21. Patients who were not able to return for all scheduled late readings were telephoned on D7, D14, and D21, and questioned about a reaction at the patch test sit…

AdultMalemedicine.medical_specialtyAllergyTime FactorsMedizinDermatologyPhenylenediaminesGastroenterology030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compoundYoung Adult0302 clinical medicineImmunopathologyInternal medicineImmunology and AllergyMedicineHumans030212 general & internal medicineProspective cohort studySensitizationbusiness.industryPatch testp-PhenylenediamineMiddle AgedPatch Testsmedicine.disease3. Good healthSurgerymedicine.anatomical_structurechemistryPatch test sensitizationDermatitis Allergic ContactFemalebusinessContact dermatitis
researchProduct

Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.

2018

BACKGROUND Previous reports indicate that patients with chronic spontaneous urticaria (CSU) are undertreated and that physicians show poor adherence to guideline recommendations. Awareness of CSU has improved in recent years, but it remains unclear if this has improved the management of these patients in clinical practice. OBJECTIVE To describe disease burden, quality of life (QoL), and treatment patterns of patients with H1 -antihistamine-refractory CSU in Germany. METHOD A World-wide Antihistamine-Refractory chronic urticaria (CU) patient Evaluation (AWARE) is a global prospective, non-interventional study of CU in the real-world setting, supported by the manufacturer of omalizumab. Patie…

0301 basic medicineAdultMalemedicine.medical_specialtymedicine.medical_treatmentImmunologyMedizinDrug ResistanceOmalizumabOmalizumab03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicinemedicineImmunology and AllergyHumansClinical significanceChronic UrticariaDisease burdenAngioedemabusiness.industryGuidelineDermatology Life Quality IndexMiddle Aged030104 developmental biology030228 respiratory systemHistamine H1 AntagonistsQuality of LifeAntihistamineFemalemedicine.symptombusinessmedicine.drugFollow-Up StudiesClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
researchProduct

Psoriasis predisposition and occupational triggering factors in the appraisal of occupational medical expertises

2014

Summary Background Psoriasis is an immune-mediated disease with a genetic background. Local psoriatic changes can be triggered by exogenous mechanical or irritant factors. Causative occupational factors have to be distinguished from the spontaneous course of psoriasis in occupational medical evaluations. The objective of this work is to demonstrate the medico-legal grounds for a homogenous assessment. Patients and methods The presented recommendations were developed in a working group for Occupational and Environmental Dermatology (ABD) and the German contact dermatitis group (DKG) of the German Dermatologic Society (DDG) based on the German medico-legal framework. Results Causality between…

medicine.medical_specialtyRehabilitationbusiness.industrymedicine.medical_treatmentDermatologyGuidelineDiseasemedicine.diseaseCausalitylanguage.human_language3. Good healthSurgeryGermanExpert witnessPsoriasisFamily medicinemedicinelanguagePosition paperbusinessJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct